Novelix Pharmaceuticals Ltd (536565)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 11 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 29 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Novelix Pharmaceuticals Ltd 11 நவ. 2026 அன்று Q2 FY27 காலாண்டு முடிவுகளை வெளியிட்டது: வருவாய் ₹44.7 கோடி (ஆண்டுக்கு ஆண்டு +23.0%, முந்தைய காலாண்டை விட +21.2%), நிகர லாபம் ₹1.6 கோடி (ஆண்டுக்கு ஆண்டு +194.9%); செயல்பாட்டு லாப வரம்பு 4.7% ஆக இருந்தது.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹44.7 | +23.0% | +21.2% |
| செயல்பாட்டு லாபம் | ₹2.1 | +203.5% | +63.5% |
| நிகர லாபம் | ₹1.6 | +194.9% | +32.6% |
| EPS (₹) | 0.57 | +54.1% | +16.3% |
| செயல்பாட்டு லாப வரம்பு | 4.7% | — | — |
- லாபம் அதன் சொந்தப் போக்கை விட +47% மேலே
- செயல்பாட்டு லாப வரம்பு 282 bps YoY அதிகரித்தது
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹1.9 கோடி லாபத்தில், ₹1.9 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது. முக்கிய லாபம் (செயல்பாட்டு லாபத்தில் வட்டி மற்றும் தேய்மானத்தைக் கழித்தது) YoY அடிப்படையில் +170.5% மாறியுள்ளது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹1.6 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹1.1 கோடியுடன் ஒப்பிடும்போது +47.5% ஆகும் (above trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Novelix Pharmaceuticals reported Q2 FY27 revenue from operations of ₹44.73 Cr (₹4,473.12 Lakhs), up 23% YoY from ₹36.36 Cr. Standalone net profit for the quarter came in at ₹1.56 Cr (₹156.32 Lakhs), a 193% surge compared to ₹0.53 Cr in Q2 FY26. For H1 FY27, total revenue reached ₹81.65 Cr with net profit of ₹2.74 Cr. However, operating cash flow for H1 remained negative at -₹13.67 Cr due to substantial working capital lockup in trade receivables.
- Revenue from operations stood at ₹4,473.12 Lakhs (₹44.73 Cr) in Q2 FY27 vs ₹3,635.89 Lakhs in Q2 FY26
- Net profit increased to ₹156.32 Lakhs (₹1.56 Cr) for the quarter vs ₹53.31 Lakhs in the prior-year period
- H1 FY27 net profit reached ₹274.21 Lakhs (₹2.74 Cr) compared to ₹64.03 Lakhs in H1 FY26
- Net cash used in operating activities stood negative at -₹1,366.50 Lakhs (-₹13.67 Cr) for H1 FY27, burdened by receivables
- Trade receivables increased sharply to ₹10,574.03 Lakhs (₹105.74 Cr) as of Sept 30, 2026, from ₹5,896.15 Lakhs as of March 31, 2026
Novelix Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 3:00 PM IST via Video Conferencing. The company has fixed September 23, 2026, as the cut-off date to determine shareholder eligibility for remote e-voting. Remote e-voting will run from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM). The share transfer books and register of members will remain closed from September 24 to September 30, 2026.
- 32nd AGM scheduled for September 30, 2026 at 03:00 PM via Video Conferencing
- Cut-off date for e-voting eligibility set as September 23, 2026
- Remote e-voting window open from September 27, 2026 (09:00 AM) to September 29, 2026 (05:00 PM)
- Book closure period runs from September 24, 2026 to September 30, 2026
Novelix Pharmaceuticals Limited has approved the appointment of Mr. Gnana Prakash Gattu as a Whole-time Director for a 5-year term effective August 29, 2026, subject to shareholder approval at the ensuing AGM. Mr. Gattu belongs to the promoter group and brings over 25 years of experience in management and information technology. The appointment formalizes leadership at the executive level as the micro-cap company navigates a TTM revenue base of Rs 4 Cr and TTM net losses of Rs -3 Cr.
- Appointed Mr. Gnana Prakash Gattu as Whole-time Director for a 5-year tenure effective August 29, 2026.
- Appointment is subject to shareholder approval at the ensuing Annual General Meeting.
- Appointee is an IIT-Chennai graduate with over 25 years of experience in management and IT.
- Mr. Gattu belongs to the Promoter and Promoter group of the company.
Novelix Pharmaceuticals has scheduled its 32nd Annual General Meeting (AGM) for September 30, 2026, with the voting cut-off date set for September 23, 2026. The Board approved the appointment of Mr. Gnana Prakash Gattu as Whole-time Director for a 5-year term effective August 29, 2026, subject to shareholder approval. Mr. Gattu belongs to the promoter group and brings over 25 years of IT and management experience. Register of members will remain closed from September 24 to September 30, 2026.
- Gnana Prakash Gattu appointed as Whole-time Director for a 5-year term starting August 29, 2026.
- 32nd Annual General Meeting convened for September 30, 2026, at 03:00 PM via Video Conferencing.
- E-voting cut-off date fixed as September 23, 2026; book closure from September 24 to September 30, 2026.
- Appointed M/s. Bharat Khaniwal & Co., PCS, as the scrutinizer for the AGM e-voting process.
Novelix Pharmaceuticals has scheduled a meeting of its Board of Directors on Saturday, August 29, 2026. The primary agenda items include approving the notice and schedule for the company's 32nd Annual General Meeting (AGM) and approving the Board Report for the financial year ended March 31, 2026. The board will also consider appointing a scrutinizer for remote e-voting and evaluate the appointment of Mr. Gnana Prakash Gattu as Whole Time Director. This is a standard corporate compliance and administrative update.
- Board meeting scheduled for Saturday, August 29, 2026
- To consider and approve the Notice for the 32nd Annual General Meeting
- To approve the Board Report for the financial year ended March 31, 2026
- Proposal to consider appointment of Mr. Gnana Prakash Gattu (DIN: 00517921) as Whole Time Director
Novelix Pharmaceuticals has entered into a 5-year lease agreement for approximately 0.925 acres (37 Guntas) of land in Siddipet District, Telangana. The site is intended for setting up micro algae cultivation and glass reactor systems. The land is leased from Mr. Gnana Prakash Gattu, a Non-Executive Director and promoter group member, at a monthly rent of Rs 5,000 plus taxes, escalating 5% every three years. Given the annual rental cost of Rs 60,000 against TTM revenue of Rs 4 Cr, the immediate financial commitment is nominal.
- Leased 37 Guntas (approx. 0.925 Acres) in Markook Village, Siddipet District, Telangana
- 5-year lease term effective from 19th August 2026
- Monthly rental of Rs 5,000 plus taxes, with a 5% increase every three years
- Purpose: Establish facilities for Micro Algae Cultivation and Glass Reactor Systems
- Related-party transaction executed with Non-Executive Director & promoter group member Gnana Prakash Gattu
Novelix Pharmaceuticals has reported zero deviation in the utilization of funds raised for the quarter ended June 30, 2026. The company had allocated Rs 421.50 Lakhs (approximately Rs 4.22 Cr) for long-term funding, working capital, and general corporate purposes. The entire amount of Rs 421.50 Lakhs has been utilized as per the original objects. This fundraise is significant as it represents approximately 105% of the company's TTM revenue of Rs 4 Cr.
- Total funds allocated for working capital and corporate purposes: Rs 421.50 Lakhs
- Total funds utilized as of June 30, 2026: Rs 421.50 Lakhs
- Amount of deviation or variation reported for the quarter: Nil
- Fundraise magnitude relative to TTM revenue: ~105%
- The statement was reviewed and approved by the Audit Committee on August 13, 2026
Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported a significant scale-up in operations for Q1 FY27, with revenue reaching Rs 36.91 Cr, a 65% increase from Rs 22.35 Cr in the same quarter last year. Net profit surged to Rs 1.18 Cr from a low base of Rs 0.11 Cr YoY, reflecting the company's transition into the API (Bulk Drugs) segment. While the top-line growth is substantial, the business remains a low-margin operation with total expenses accounting for 97% of revenue. The company's paid-up equity capital also increased to Rs 23.90 Cr during the quarter.
- Revenue from operations grew 65.1% YoY to Rs 36.91 Cr from Rs 22.35 Cr.
- Net profit increased more than 10-fold to Rs 1.18 Cr compared to Rs 0.11 Cr in the year-ago period.
- Purchases of stock-in-trade remained the largest cost component at Rs 31.93 Cr, indicating a trading-heavy model.
- Paid-up equity share capital increased to Rs 23.90 Cr from Rs 21.09 Cr in the preceding quarter.
- The company has fully transitioned to a single business segment: Manufacturing and Trading of APIs.
Novelix Pharmaceuticals has scheduled a board meeting for August 13, 2026, to approve unaudited standalone financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of ₹70 Cr and is currently loss-making with a TTM PAT of -₹3 Cr. Investors should note the recent increase in promoter holding from 49.43% in March 2026 to 54.29% in July 2026. The trading window for designated persons has been closed since July 1, 2026, and will remain so until 48 hours after the results are declared.
- Board meeting scheduled for August 13, 2026, to approve Q1 results
- Financial results pertain to the quarter ended June 30, 2026
- Trading window closed from July 01, 2026, until 48 hours post-meeting
- Company TTM revenue is ₹4 Cr against a market cap of ₹70 Cr
- Promoter holding increased to 54.29% as of July 2026
Novelix Pharmaceuticals has allotted 100,000 equity shares to Neha Gattu, a member of the promoter group, following the conversion of warrants on July 9, 2026. This transaction increased the total promoter group holding from 500,000 to 600,000 shares. Concurrently, the company's total equity base expanded significantly from 23.89 million to 28.47 million shares. Consequently, the promoter group's stake marginally increased from 2.09% to 2.11% of the expanded capital.
- 100,000 equity shares allotted to Neha Gattu on July 9, 2026, via warrant conversion.
- Total promoter group holding (including PACs) increased to 600,000 shares.
- Company's total equity share capital expanded by 4,575,000 shares to reach 28,470,000 shares.
- Promoter group stake stands at 2.11% post-allotment, up from 2.09%.
- The conversion was part of a preferential allotment basis previously approved.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
